Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Avalo Therapeutics ( (AVTX) ) is now available.
On October 1, 2025, Avalo Therapeutics announced the appointment of Taylor Boyd as Chief Business Officer and Ashley Ivanowicz as Senior Vice President of Human Resources. These appointments are part of Avalo’s strategic efforts to strengthen its leadership team as it advances its lead asset, AVTX-009, through clinical trials. Taylor Boyd brings extensive experience in biotech business development and corporate finance, while Ashley Ivanowicz offers nearly 20 years of HR expertise in the biotech and pharmaceutical sectors. The appointments are expected to enhance Avalo’s strategic direction and organizational growth, supporting the company’s mission to deliver meaningful therapies for patients.
The most recent analyst rating on (AVTX) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Avalo Therapeutics stock, see the AVTX Stock Forecast page.
Spark’s Take on AVTX Stock
According to Spark, TipRanks’ AI Analyst, AVTX is a Neutral.
The overall stock score for Avalo Therapeutics is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. Despite positive technical indicators suggesting bullish momentum, the negative valuation metrics due to ongoing losses weigh heavily on the stock’s attractiveness.
To see Spark’s full report on AVTX stock, click here.
More about Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. Their lead asset, AVTX-009, is currently in a Phase 2 clinical trial for hidradenitis suppurativa, and the company is exploring additional opportunities in prevalent indications with significant unmet needs.
Average Trading Volume: 296,447
Technical Sentiment Signal: Sell
Current Market Cap: $171.2M
See more insights into AVTX stock on TipRanks’ Stock Analysis page.